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Abstract
Introduction: Hyperferritinemia is associated with increased mortality in pediatric sepsis, multiple organ
dysfunction syndrome (MODS), and critical illness. The International Histiocyte Society has recommended that
children with hyperferritinemia and secondary hemophagocytic lymphohistiocytosis (HLH) or macrophage
activation syndrome (MAS) should be treated with the same immunosuppressant/cytotoxic therapies used to treat
primary HLH. We hypothesized that patients with hyperferritinemia associated secondary HLH/sepsis/MODS/MAS
can be successfully treated with a less immunosuppressant approach than is recommended for primary HLH.
Methods: We conducted a multi-center cohort study of children in Turkish Pediatric Intensive Care units with
hyperferritinemia associated secondary HLH/sepsis/MODS/MAS treated with less immunosuppression (plasma
exchange and intravenous immunoglobulin or methyl prednisolone) or with the primary HLH protocol (plasma
exchange and dexamethasone or cyclosporine A and/or etoposide). The primary outcome assessed was hospital
survival.
Results: Twenty-three children with hyperferritinemia and secondary HLH/sepsis/MODS/MAS were enrolled
(median ferritin = 6341 μg/dL, median number of organ failures = 5). Univariate and multivariate analyses
demonstrated that use of plasma exchange and methyl prednisolone or intravenous immunoglobulin (n = 17,
survival 100%) was associated with improved survival compared to plasma exchange and dexamethasone and/or
cyclosporine and/or etoposide (n = 6, survival 50%) (P = 0.002).
Conclusions: Children with hyperferritinemia and secondary HLH/sepsis/MODS/MAS can be successfully treated
with plasma exchange, intravenous immunoglobulin, and methylprednisone. Randomized trials are required to
evaluate if the HLH-94 protocol is helpful or harmful compared to this less immune suppressive and cytotoxic
approach in this specific population.
* Correspondence: d-demirkol@hotmail.com
1Department of Pediatric Intensive Care, Bezmialem Vakif University, Faculty
of Medicine, Vatan Caddesi, Istanbul, 34093, Turkey
Full list of author information is available at the end of the article
Demirkol et al. Critical Care 2012, 16:R52
http://ccforum.com/content/16/2/R52
© 2012 Demirkol et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a life-
threatening disorder that can rapidly deteriorate and
lead to multiple organ failure (MOF) and death [1,2]. It
is classified as primary (familial) or secondary (acquired)
[3,4]. Primary HLH is an autosomal recessive disorder
caused by a number of different perforin signaling muta-
tions [5]. Secondary HLH is associated with viral, bac-
terial, fungal, and parasitic infections and malignant
disorders [4] in patients without this autosomal reces-
sive disorder. Autoimmune disease-associated HLH is
classified as macrophage activation syndrome (MAS) [6].
Hemophagocytic disorders result when critical regula-
tory pathways responsible for the natural termination of
immune/inflammatory responses are disrupted or over-
whelmed. Hemophagocytic lymphohistiocytosis is char-
acterized by multisystem inflammation, a reactive
process resulting from prolonged and intense activation
of antigen-processing cells (macrophages and histio-
cytes) and CD8+ T cells, and excessive proliferation and
ectopic migration of T cells. Studies of cytokine levels in
blood and tissue have indicated persistently elevated cir-
culating levels of multiple pro-inflammatory cytokines
during symptomatic disease [7-9]. It is currently believed
that ‘hypercytokinemia’ and possibly ‘hyperchemokine-
mia’ generated by uncontrolled activation of histiocytes
cause MOF.
According to guidelines of the International Histiocyte
Society, a diagnosis of HLH requires at least five of the
following eight criteria are met: fever, splenomegaly,
cytopenias, hypertriglyceridemia or hypofibrinogenemia
(or both), hyperferritinemia, elevated soluble interleu-
kin-2 receptor alpha (IL-2Ra), decreased natural killer
(NK) cell activity, and hemophagocytosis in bone mar-
row [4]. Unfortunately, the diagnosis of HLH is compli-
cated by its relatively non-specific clinical presentation.
Although hypercytokinemia is a hallmark of HLH, it has
also been associated with sepsis, systemic inflammatory
response syndrome (SIRS), and multiple organ dysfunc-
tion syndrome (MODS) [10,11]. Soluble IL-2Ra is sensi-
tive and specific for HLH [12] but is also elevated in
sepsis/MODS/MAS. Of the various laboratory variables
available for HLH diagnosis, the most widely used is fer-
ritin. Ferritin is a ubiquitous iron-binding protein that
regulates iron storage and homeostasis. The ferritin
heavy-chain gene also positively regulates pro-inflamma-
tory cytokine signaling through the nuclear factor-
kappa-B pathway [13]. Hyperferritinemia is frequently
seen in the intensive care unit, is a marker of a final
common pathway of systemic inflammatory response,
and is associated with the severity of the underlying dis-
ease [14,15]. Bennett and colleagues [15] showed that
the hazard ratio of death with peak ferritin of greater
than 3,000 ng/mL was 4.32. Hyperferritinemia has also
been associated with HLH and many other inflamma-
tory conditions such as sepsis, SIRS, MODS, and MAS
[16,17].
According to the International Histiocyte Society
guidelines, the treatment for HLH involves an initial 8
weeks of chemoimmune therapy [4]. The immediate aim
of chemotherapy in HLH is suppression of the increased
inflammatory response and control of cell proliferation.
Clinical case series and case reports and animal models
suggest that implementation of the HLH protocol has
resulted in improved survival in primary HLH; however,
the beneficial effect of the protocol for patients with
secondary HLH or MAS is questioned. In an effort not
to delay treatment in patients with primary HLH, the
International Histiocyte Society recommends treating
hyperferritinemia-associated secondary HLH/sepsis/
MODS/MAS with the same protocol used for primary
HLH. In contrast, our hypothesis is that hyperferritine-
mia-associated secondary HLH/sepsis/MODS/MAS can
be successfully treated with a less immunosuppressive
and cytotoxic approach than is recommended for pri-
mary HLH.
We performed an observational cohort study to evalu-
ate outcome in children with hyperferritinemia and sec-
ondary HLH/sepsis/MODS/MAS and compared those
who received plasma exchange (PE) with intravenous
immunoglobulin (IVIG) or methylprednisone or both
with those who received PE with the HLH-94 protocol.
We hypothesized that hospital survival would be better
with the less immunosuppressive/cytoxic approach.
Materials and methods
We performed the observational cohort study between
December 2005 and April 2011. The study was
approved by the ethics committee of the Istanbul
Faculty of Medicine (reference number 2011/205-469).
Informed consent to participation in the study and to
publication of this article was obtained from the guar-
dians of the patients.
Eight centers participated in the Turkish Secondary
HLH/MAS Critical Care Study Group. Patients who had
secondary HLH and MAS were entered in the study.
The patients with primary HLH were excluded from the
study. The sample size was estimated a priori to be 20
patients with hyperferritinemia and secondary HLH/
MAS. A standardized study form, developed by all parti-
cipating pediatric intensive care centers, was filled in for
each patient by the responsible pediatric intensivists
from each center. The form consisted of patient age,
gender, primary disease, underlying disease, consangui-
nity, family history of HLH, Pediatric Risk of Mortality
III (PRISM III) score, Pediatric Logistic Organ
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Dysfunction (PELOD) score, numbers of organs involved
and the type of organ involvement, microbiological and
laboratory data, respiratory support, treatment protocols
used, and hospital mortality. The severity of illness was
classified by using the PRISM III score and calculated
from the most abnormal values in the first 24 hours
after admission [18]. Organ dysfunctions were scored
according to the PELOD scoring system [19].
The HLH/MAS was diagnosed if five of the following
eight criteria were met: (a) fever, (b) splenomegaly, (c)
cytopenias (at least two of the following: hemoglobin of
less than 9 g/L, platelet count of fewer than 100 × 109/L,
and neutrophil count of fewer than 1.0 × 109/L), (d) hyper-
tryglyceridemia (at least 265 mg/dL) or hypofibrinogen-
emia (not more than 150 mg/L) or both, (e) bone marrow
hemophagocytosis, (f) hyperferritinemia (greater than 500
μg/L), (g) increased soluble CD25, and (h) absent NK
activity. Patients were not routinely tested for sCD25 levels
or NK cell activity; however, all were tested for ferritin
levels and bone marrow hemophagocytosis. The patient
was classified as having primary HLH if there was a severe
clinical presentation without a proven or suspected infec-
tion history or metabolic disease and at least one of the
following criteria: family history or parental consanguinity,
presentation before the age of 2 years, severe clinical pre-
sentation with central nervous system involvement, or per-
sistence or recurrence of HLH [4]. Therefore, the children
in our study were classified with secondary HLH/MAS
because they had suspected or proven infection, no family
history or parental consanguinity, were 2 years old or
older, had no central nervous system involvement, and
had no prior history of HLH. MAS was defined in our
cohort in patients who met HLH criteria with an underly-
ing autoimmune disease [5]. SIRS, infection, sepsis, severe
sepsis, and septic shock were defined according to the
guidelines of the International Pediatric Sepsis Consensus
Conference [20]. Treatment failure was defined as progres-
sive disease despite therapy.
The PE treatments were performed by a continuous fil-
tration technique (Prisma; Gambro, Lund, Sweden) in five
centers with a polypropylene hollow-fiber plasma filter
(TPE 2000; Gambro) and by centrifugation technique
(Spectra Optica; CardianBCT, Lakewood, CO, USA, and
Com.Tec; Fresenius HemoCare GmbH, Bad Homburg,
Germany) in three centers; a Spectra Optia tubing set and
a PL-1 kit in a dual-needle set, respectively, were used.
Vascular access was obtained with a double-lumen cathe-
ter placed percutaneously in a central vein. Total plasma
volume (TPV) was calculated manually according to this
formula: TPV = total blood volume × (1 - hematocrit).
Anticoagulation was achieved with heparin. An infusion of
heparin was titrated to achieve an activated partial throm-
boplastin time (aPTT) of between 50 and 70 seconds. No
life-threatening complication related to line placement
and PE procedure during the study period was seen.
Serum ferritin and lactate dehydrogenase levels and plate-
let counts were recorded at admission and before and
after each PE session.
Statistical analysis
All statistical analysis were performed by using the Sta-
tistical Package for Social Sciences (SPSS 10; SPSS Inc.,
Chicago, IL, USA). Categorical end points were com-
pared by using the chi-squared test. If continuous vari-
ables were normal, they were described as the mean ±
standard deviation (P > 0.05 in Shapiro-Wilk test), and
if the continuous variables were not normal, they were
described as the median. The continuous variables were
compared by using Mann-Whitney U analysis. Factors
associated with a P value of less than 0.1 in univariate
analysis were further evaluated in a multiple regression
analysis. A P value of less than 0.05 was considered sig-
nificant in the multiple regression analysis.
Results
The eight centers identified 34 patients with hyperferri-
tinemia and MODS. Primary HLH was diagnosed in five
patients and was treated with the HLH-94 protocol, and
the patients had 50% survivals and were excluded from
the study. Six patients did not meet five of the eight cri-
teria required for a diagnosis HLH/MAS and were
excluded from further analysis. Secondary HLH/MAS
was diagnosed in 23 patients, who met criteria for analy-
sis and whose data are presented herein. According to
the International Pediatric Sepsis Consensus definitions,
56% (n = 13) of these patients also met the diagnostic
criteria for septic shock and 9% (n = 2) for severe sepsis.
The characteristics and clinical presentations of these 23
patients with secondary HLH/sepsis/MODS/MAS are
presented in Tables 1 and 2.
Table 1 Baseline characteristics of patients with
hyperferritinemia and secondary HLH/sepsis/MODS/MAS
Variable Patients with secondary HLH/MAS
(n = 23)
Mean ± SD Median Range
Age, years 7.2 ± 3.6 6.7 2-15
PRISM III-24 score 23.9 ± 12.5 19.5 7-48
PELOD score 26 ± 13.8 24 4-53
Number of dysfunctional organs 4.6 ± 1 5 3-6
Percentage Number
Males/Females 74/26 17/6
Artificial ventilation 87 20
Underlying disease 78 18
HLH, hemophagocytic lymphohistiocytosis; MAS, macrophage activation
syndrome; MODS, multiple organ dysfunction syndrome; PELOD, Pediatric
Logistic Organ Dysfunction; PRISM, Pediatric Risk of Mortality; SD, standard
deviation.
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Sixty-five percent of the 23 patients (n = 15) were
classified as having secondary HLH. Thirty-five percent
of the patients (n = 8) were classified as having MAS:
juvenile rheumatoid arthritis (n = 6), systemic lupus
erytheromatosis (n = 1), and polyarteritis nodosa (n =
1). All of the patients had hyperferrtinemia as well as
hemophagocytosis in their bone marrow aspirate (Figure
1). The diagnostic laboratory variables of the patients
with secondary HLH/MAS are presented in Table 3. An
underlying disease was present in 78% (n = 18) of the
patients (Table 1). The precipitating factors in patients
with secondary HLH/MAS were viral and non-viral
infections in 93% (n = 14) of the patients. The microbio-
logical agents were Varicella zoster virus (n = 3), Acine-
tobacter baumannii, Salmonella enteritidis, Eschericia
coli (n = 2), Staphylococcus aureus, Stenotrophomonas
maltophilia, Candida albicans, Epstein-Barr virus, and
H1N1 virus infection. In one patient with secondary
HLH, no precipitating factors were found. The precipi-
tating factors in patients with MAS were drugs in three
patients, namely naproxen sodium, cefepime, and ampi-
cillin-sulbactam. The precipitating factor was infection
in one patient with MAS (Burcholderia cepacia). In four
patients with MAS, no precipitating factors other than
autoimmune disease were found.
During the study period, patients with hyperferritine-
mia and secondary HLH/sepsis/MODS/MAS were
assigned to one of four different treatment protocols
according to center preference. In protocol 1, the
patients (n = 8) received PE or intravenous methylpred-
nisolone or both. PE was performed by using a rapid
exchange of 1.5 estimated TPVs in the first PE session
and then a lower exchange rate with one estimated TPV
every 24 hours. Intravenous methylprednisolone was
given at 30 mg/kg for 3 days, 20 mg/kg for 2 days, 10
mg/kg for 2 days, 5 mg/kg for 2 days, and then 2 mg/
kg. Intravenous methylprednisolone was not used in two
patients in protocol 1, because of severe Varicella infec-
tion. In protocol 2, the patients (n = 9) received PE and
IVIG. PE was performed by using 1.5 estimated TPVs
every 24 hours, and IVIG was given at a dose of 1 g/kg.
In protocol 3, the patients (n = 4) received the HLH-
94 protocol (intravenous dexamethasone 10 mg/m2,
intravenous cyclosporine A 6 mg/kg, or intravenous eto-
poside 150 mg/m2) and IVIG 2 g/kg. If treatment failure
was determined, then PE was performed with 1.5 esti-
mated TPVs every 24 hours. In protocol 4, the patients
(n = 2) received dexamethasone 10 mg/m2 and IVIG 1
g/kg. If treatment failure was determined, then PE was
performed with one estimated TPV.
In all eight centers, PE was performed in patients with
hyperferritinemia and more than two organ dysfunc-
tions. PE was continued until organ dysfunctions
resolved, ferritin levels decreased, and platelet count
increased greater than 100,000/mm3. PE was performed
median 5 (1 to 18) times, and PE median doses were 1.5
estimated TPVs and 78 mL/kg (60 to 80). The serum
ferritin and lactate dehydrogenase levels decreased and
platelet counts increased gradually after each PE ses-
sions (Figure 2).
The overall mortality was 13% (n = 3). Mortality rates
were 50% (2/4) and 50% (1/2) in the patients with sec-
ondary HLH/sepsis/MODS/MAS treated with che-
motherapy and dexamethasone-based treatment
protocols (protocols 3 and 4, respectively). Despite ther-
apy, two patients died because of progressive MOF and
one patient died because of pulmonary bleeding. Two of
the non-survivors had a culture-positive infection. There
were no deaths in children who were not treated proto-
cols based on dexamethasone, cyclosporin A, or
etoposide.
We compared demographic variables, laboratory para-
meters, and use of treatment protocols as they related
to outcome in the survivors and non-survivors (Table
Table 2 Diagnostic findings of patients with hyperferritinemia and secondary HLH/sepsis/MODS/MAS
Variable Secondary HLH/MAS (n = 23), percentage (number)
Fever 100 (23)
Splenomegaly 65 (15)
Cytopenia 96 (22)
Anemia 96 (22)
Thrombocytopenia 91 (21)
Neutropenia 44 (10)
Hypertriglyceridemia 87 (20)
Hypofibrinogenemia 39 (9)
Hyperferritinemia 100 (23)
Hemophagocytosis in bone marrow 100 (23)
Survival 87 (20)
All of the patients met five or more of the criteria required for a diagnosis of hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS).
HLH, hemophagocytic lymphohistiocytosis; MAS, macrophage activation syndrome; MODS, multiple organ dysfunction syndrome.
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4). There were differences between survivors and non-
survivors in regard to gender, serum ferritin levels, and
treatment protocols (all P < 0.1). In the multiple regres-
sion analysis, gender, serum ferritin level, and treatment
protocols were independent variables. Survival was best
explained by the treatment protocol used (R = 0.55, b =
0.6, P = 0.001, 95% confidence interval (CI) 0.1 to 0.33)
even after ferritin levels and gender were controlled for.
Ferritin levels also predicted survival (R = 0.74, b = 0.4,
P = 0.004, 95% CI 0.0001 to 0.0008) but gender did not.
We further compared demographic variables and
laboratory parameters between the ‘PE and methylpred-
nisolone or IVIG treated group’ and the ‘PE and che-
motherapy or dexamethasone treated group’ (Table 5).
There were differences between treatment protocol use
in regard to gender, prothrombin time (PT), aPTT
levels, and alanine aminotransferase (ALT) levels (P <
0.1). In the multiple regression analysis, in which gen-
der, PT, aPTT, ALT levels, and treatment protocol were
controlled for, only treatment protocol remained asso-
ciated with survival (R = 0.84, b = 0.79, P = 0.03, 95%
CI 0.8 to 1.5).
Discussion
The severity of the condition of the patients in our
cohort study is illustrated by the median ferritin level
of 6,341 μg/dL and the presence of severe MODS/
MOF. According to Bennett and colleagues [15],
higher levels of ferritin (> 3,000 ng/mL) are associated
with increased mortality in a dose response fashion,
and Garcia and colleagues [17] reported 100% mortal-
ity in children with high ferritin levels and severe
 
Figure 1 Bone marrow smears show activated macrophages and hemophagocytosis from bone marrow puncture. Photomicrographs of
a bone marrow aspirate smear show large histiocytes (with vacuolated cytoplasm containing nuclear debris and whole red blood cells). Stain:
Wright-Giemsa. Magnification: 1,000×.
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sepsis. Additionally, the children in our study had a
median of five dysfunctioning organs, for which prog-
nosis is considered very poor [21]. According to
Leclerc and colleagues [22], there is a cumulative influ-
ence of organ dysfunction and the septic state on mor-
tality of critically ill children. Furthermore, given that
over half of our patients had septic shock/severe sepsis,
the expected mortality of patients with sepsis in our
cohort was 92% [22]. The survival observed in our
study was significantly better than expected.
It is of major importance for critical care physicians to
be aware that the clinical picture of hemophagocytosis
encountered during HLH, sepsis, MODS, and MAS can
overlap and share common features. These syndromes
cannot be reliably discriminated by using diagnostic cri-
teria devised for HLH [1,16,23,24]. Many patients with
HLH will progress to develop MODS, which is also seen
in patients with severe sepsis [1,2]. Of the 122 children
reported to have HLH in 1996, only 25 met the more
strict genetic criteria of familial HLH; the rest of the
children were deemed to have secondary HLH. A variety
of primary infections were present in 41% of these sec-
ondary HLH cases [25]. Hemophagocytosis has been
described in 64.5% of 107 autopsies in critically ill medi-
cal patients with thrombocytopenia-associated MOF,
and all patients with hemophagocytosis had infection
[26]. Castillo and Carcillo [16] reviewed the shared clini-
cal similarities between secondary HLH, severe sepsis,
SIRS, MODS, and MAS and concluded that these enti-
ties could be considered intermediate phenotypes of the
same inflammatory process.
According to the International Histiocyte Society
guidelines, the treatment of HLH involves chemoim-
mune therapy. However, some investigators question
whether these patients, especially those with sepsis-asso-
ciated hemophagocytsosis, should receive immunosup-
pression treatment even when HLH criteria are met.
Patients with secondary HLH treated with chemother-
apy-based protocols have had only a 55% survival at 3
years, and early mortality was related to hemorrhages
and infections [27]. An HLH series of 20 patients
showed a mortality rate of 60%, and deaths were attribu-
ted to invasive infections in eight cases [28]. In a pre-
vious Turkish pediatric cohort, Karapınar and colleagues
[2] reported that survival was 43% in critically ill pedia-
tric patients whose HLH and MODS were treated with
the HLH-94 2004 protocol. Recently published adult
data showed an 89% mortality in patients with virus-
associated hemophagocytic syndrome treated with che-
moimmune therapy [29]. By contrast, in the present
study, 65% of the patients with hyperferritinemia and
MODS had active infections and the survival was 100%
in the group were not treated with chemotherapeutics
or dexamethasone.
All patients in our cohort study received PE therapy.
PE is an extracorporeal blood purification technique
designed to remove various toxic and inflammatory
mediators and to replenish essential compounds via the
replacement plasma. PE therapy reverses HLH, possibly
by decreasing circulating inflammatory cytokines,
including macrophage colony-stimulating factor (M-
CSF) [30,31]. There have also been anecdotal reports of
patients with secondary HLH/MAS successfully treated
with PE [30-32]. In the present study, PE was used as
standard care for patients with secondary HLH/MAS to
control hypercytokinemia. Several studies favor the use
of PE in severely ill septic patients with MODS and
thrombocytopenia-associated MOF [33-35]. Stegmayr
and colleagues [36] reported a beneficial effect of PE as
supportive therapy in patients with progressive dissemi-
nated intravascular coagulation and MODS, especially if
septic shock was present. In the present study, mortality
was detected only in patients who received treatment
with cyclosporine, dexamethasone, and/or etoposide.
Thus, any beneficial effects of PE might not override the
impact of chemotherapeutics in children with secondary
HLH/sepsis/MODS/MAS.
The addition of intravenous methylprednisolone and
immunoglobulins as anti-inflammatory agents may be
less toxic than the addition of dexamethasone, cyclos-
porine A, and/or etoposide. Intravenous dexamethasone
is cytotoxic for lymphocytes and inhibits expression of
cytokines and differentiation of dendritic cells. Since
dexamethasone crosses the blood-brain barrier better
than methylprednisolone, it offers the advantage of
Table 3 Laboratory variables of patients with secondary
HLH/sepsis/MODS/MAS
Variable Mean ± SD Median Range
Hemoglobin, g/dL 7.8 ± 2.1 8.1 4.8-15.0
Leukocytes,/mm3 10,260 ±
11,402
6,240 400-46,000
Absolute neutrophil count,/
mm3
7,796 ± 9,148 5,025 0-35.000
Platelet count,/mm3 59,221 ±
54,733
51,000 10,000-
235,000
PT, seconds 24.8 ± 14.3 21.7 10.3-69.0
aPTT, seconds 42.3 ± 14.5 39 24.7-74.2
Fibrinogen, mg/dL 206 ± 161 171 0-607
Triglycerides, mg/dL 555 ± 348 528 108-1,511
Albumin, g/L 2.6 ± 0.6 2.6 1.4-4.1
Sodium, mEq/L 132.2 ± 7.1 132 120-147
Alanine aminotransferase, U/L 962 ± 2,713 135 21-11,276
Lactate dehydrogenase, U/L 3,721 ± 3,071 2,300 765-100,000
Ferritin, μg/dL 25,313 ±
31,246
6,341 765-100,000
aPTT, activated partial thromboplastin time; HLH, hemophagocytic
lymphohistiocytosis; MAS, macrophage activation syndrome; MODS, multiple
organ dysfunction syndrome; PT, Prothrombin time; SD, standard deviation.
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suppressing central nervous system inflammation for
patients with primary HLH; however, the immunosup-
pressive potency of dexamethasone may be deleterious
in patients with sepsis. Hurwitz and colleagues [37]
reported the occurrence of fatal or near-fatal sepsis in
16 of 38 children with newly diagnosed acute lympho-
blastic leukemia (ALL) treated with a new induction
regimen that differed from its predecessor in that it
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Figure 2 Change of serum ferritin and lactate dehydrogenase levels and platelet counts after therapeutic plasma exchange (PE)
sessions. The serum ferritin and lactate dehydrogenase levels decreased and platelet counts gradually increased after PE sessions.
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administered long-term high-dose dexamethasone. The
investigators concluded that the substitution of dexa-
methasone for prednisone or methylprednisolone in an
otherwise intensive conventional induction regimen for
previously untreated children with ALL resulted in an
alarmingly high incidence of septic episodes and deaths
[36]. In contrast, high-dose intravenous methylpredniso-
lone treatment did not increase mortality. Etoposide and
cyclosporin A also have potent immunosuppressive and
cytotoxic effects compared with IVIG. Immunoglobulins
probably act, in part, by providing cytokine- and patho-
gen-specific antibodies. Hence, in children with active
infection, it may be better not to use agents that impair
the host’s ability to fight off infection.
There are several limitations to consider when evalu-
ating our study. By nature of the cohort design, this is
not a randomized controlled study. A randomized trial
comparing the two treatment strategies are needed. Sec-
ond, since all patients received PE therapy, the
observations in this study may or may not apply to chil-
dren who do not receive PE therapy as part of the
approach to secondary HLH/sepsis/MODS/MAS. Third,
we did not routinely measure NK cell activity or sCD25,
nor did we address perforin signaling genetics. There-
fore, our findings should not be applied to children with
primary HLH and homozygous perforin signaling muta-
tional defects. Our findings should be considered only
in children who either are heterozygous or lack these
mutations. As Behrens and colleagues [38] recently
reported, an experimental model of repeated Toll-like
receptor-9 (TLR-9) stimulation with interferon-gamma
led to HLH/MAS after endotoxin exposure in mice
without any perforin signaling mutations. Our children
may be better represented by this experimental model
of acquired HLH/MAS disease than by the well-estab-
lished congenital perforin signaling mutation knockout
mouse models of primary HLH [39]. One should strictly
use our definitions of secondary HLH/MAS (having
Table 4 Demographic characteristics and laboratory variables of survivors and non-survivors
Survivors (n = 20) Non-survivors (n = 3)
Frequency,
percentage
Number Frequency,
percentage
Number P
Females/Males 20/80 4/16 67/33 2/1 0.08
Underlying disease 80 16 67 2 0.6
Mechanical ventilation 85 17 100 3 0.5
Mean ± SD Median Range Mean ± SD Median Range P
Age, years 6.9 ± 3.3 6.7 2-14 8 ± 6.3 6.2 2.8-15.1 0.7
PRISM III-24 score 25.3 ± 13 21 7-48 14 ± 5.1 14 11-21 0.2
PELOD score 27.2 ± 14.5 25 4-53 22.3 ± 9.1 21 14-32 0.7
Number of organs involved 4.5 ± 1 5 3-6 5 ± 1 5 4-6 0.5
Hemoglobin, g/dL 7.5 ± 1.4 8 4.8-8.9 9.6 ± 4.9 8.8 5.2-15 0.4
Leukocytes,/mm3 8,814 ± 8,836 6,220 400-26,400 19,900 ±
22,981
11,000 2,700-46,000 0.3
Absolute neutrophil count,/mm3 66,688 ± 7,279 4,370 0-23,000 14,816 ±
17,783
8,030 1,450-35,000 0.3
Platelets,/mm3 59,255 ±
57,758
48,000 10,000-
235,000
59,000 ±
35,510
79,000 18,000-
80,000
0.6
PT, seconds 26.4 ± 14.9 24.9 10.3-69 15.3 ± 1.3 15.3 13.9-16.5 0.2
aPTT, seconds 41.9 ± 14.1 39 24.7-74 41.2 ± 17.2 39.4 25-59 0.5
Fibrinogen, mg/dL 201 ± 162 180 0-607 236 ± 180 156 110-443 0.2
Triglycerides, mg/dL 554 ± 349 436 122-1551 559.5 ± 417 638 108-931 0.7
Albumin, g/dL 2.6 ± 0.6 2.7 1.4-4.1 2.8 ± 0.5 2.6 2.4-3.3 0.8
Sodium, mEq/L 131 ± 6 132 120-141 141 ± 8.5 141 135-147 0.3
ALT, U/L 324 ± 585 128 21-2,362 5,751 ± 7,812 1250 227-11,276 0.14
LDH, U/L 3,884 ± 3146 2300 410-11,270 2,327 ± 2,665 2,327 443-4,212 0.6
Ferritin, μg/dL 20,124 ±
27163
5054 765-100,000 40,802 ±
34,583
40,802 16,348-
65,256
0.06
Treatment protocols Frequency Number Frequency Number 0.002
PE and chemotherapy or dexamethasone (protocols 3 and
4)
50% 3/6 50% 3/6
PE and methylprednisolone or IVIG (protocols 1 and 2) 100% 17/17 None
ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; IVIG, intravenous immunoglobulin; LDH, lactate dehydrogenase; PE, plasma exchange;
PELOD, Pediatric Logistic Organ Dysfunction; PRISM, Pediatric Risk of Mortality; PT, Prothrombin time; SD, standard deviation.
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suspected or proven infection and no family history or
parental consanguinity, being 2 years old or older, hav-
ing no central nervous system involvement, and having
no prior history of HLH) when considering the applic-
ability of our findings to one’s practice. Finally, there are
no data between outcome and gender association in
patients with secondary HLH/MAS. The female prepon-
derance seen in mortality in the present study needs
further investigation.
Conclusions
This cohort study supports the beneficial effect of PE
and less immunosuppressive and cytotoxic methylpred-
nisone and IVIG therapies in patients with hyperferriti-
nemia and secondary HLH/sepsis/MODS/MAS. No
significant difference was seen in outcome between the
more and less immunosuppressive groups, however the
less immunosuppressive therapy may have less toxic
effects than observed with the HLH-94 protocol and
should be considered. Until a randomized trial is
performed, one could consider this approach for the
treatment of secondary HLH/MAS with MODS, espe-
cially in patients with sepsis-associated HLH/MAS.
Key messages
• Hyperferritinemia-associated secondary hemopha-
gocytic lymphohistiocytosis (HLH)/sepsis/multiple
organ dysfunction syndrome (MODS)/macrophage
activation syndrome (MAS) can be successfully trea-
ted with a less immunosuppressive approach than is
recommended for primary HLH.
• Plasma exchange may be an important therapeutic
tool in the pediatric field for treatment of secondary
HLH/MAS with MODS.
Abbreviations
ALL: acute lymphoblastic leukemia; ALT: alanine aminotransferase; aPTT:
activated partial thromboplastin time; CI: confidence interval; HLH:
hemophagocytic lymphohistiocytosis; IL-2Rα: interleukin-2 receptor alpha;
IVIG: intravenous immunoglobulin; MAS: macrophage activation syndrome;
MODS: multiple organ dysfunction syndrome; MOF: multiple organ failure;
Table 5 Demographic characteristics and laboratory variables of patients with secondary HLH/MAS treated with PE
and methylprednisolone or IVIG or with PE and chemotherapy or dexamethasone
PE and methylprednisolone or IVIG (n = 17) PE and chemotherapy or dexamethasone (n = 6)
Frequency, percentage Number Frequency, percentage Number P
Males/Females 88/12 15/2 33/67 2/4 0.003
Underlying disease 77 13 83 5 0.6
Mechanical ventilation 89 15 83 5 0.5
Mean ± SD Median Range Mean ± SD Median Range
Age, years 6.8 ± 3.3 6.5 2-14 7.6 ± 4.8 6.8 2.8-15.1 0.8
PRISM III-24 score 25.6 ± 13.4 25.6 7-48 19.5 ± 8.8 17.5 11-53 0.3
PELOD score 26.2 ± 13.8 24 4-52 27.5 ± 15. 26.5 13-53 0.9
Number of organs involved 4.5 ± 1 5 3-6 4.6 ± 1 5 3-6 0.7
Hemoglobin, g/dL 7.3 ± 1.5 8 4.8-8.9 8.8 ± 3.3 8.3 5.2-15 0.4
Leukocytes,/mm3 10,145 ± 9,230 6,270 500-26,400 12,096 ± 17189 6,500 400-46,600 0.9
Absolute neutrophil count,/mm3 7,420 ± 7,598 7,420 100-23,300 8,801 ± 13,291 4,475 0-35,000 0.6
Platelet,/mm3 51,594 ± 42,767 45,000 10,000-187,000 80,833 ± 81,052 70,000 12,000-235,000 0.6
PT, seconds 29.2 ± 14.68 25 13-69 14 ± 2.1 14.1 10.3-16.5 0.004
aPTT, seconds 45.2 ± 13.1 45.8 30-74 33.2 ± 14 25.7 24.7-59.3 0.05
Fibrinogen, mg/dL 188.3 ± 169 148.5 0-607 206 ± 139 206 110-443 0.2
Triglycerides, mg/dL 515 ± 275 450 122-1,094 654 ± 507 547 108-1,511 0.9
Albumin, mg/dL 2.6 ± 0.7 2.7 1.4-4.1 2.7 ± 0.3 2.6 2.4-3.3 0.9
Sodium, mEq/L 131 ± 6.9 131 120-141 136 ± 6.7 135 130-147 0.1
LDH, U/L 42,10 ± 3306 2,300 750-11,270 2,349 ± 1,934 2,310 410-4,374 0.4
ALT, U/L 310 ± 627 100 21-2,362 3,080 ± 5,466 409 227-11,276 0.03
Ferritin, μg/dL 20,538 ± 28,199 5,109 765-100,000 38,844 ± 38,130 31,718 2,998-97,767 0.2
MV duration, days 18.7 ± 17.4 12 2-65 20 ± 25 5 1-60 0.6
PICU LOS, days 23 ± 18.8 16 4-69 21.6 ± 23 12.9 1-60 0.5
Hospital LOS, days 43.9 ± 33.7 30 11-110 39.2 ± 26.3 41.5 5-70 0.8
Frequency Number Frequency Number
Survival 100% 17 50% 3 0.002
ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; HLH, hemophagocytic lymphohistiocytosis; IVIG, intravenous immunoglobulin; LDH,
lactate dehydrogenase; LOS, length of stay; MAS, macrophage activation syndrome; MV, mechanical ventilation; PE, plasma exchange; PELOD, Pediatric Logistic
Organ Dysfunction; PICU, pediatric intensive care unit; PRISM, Pediatric Risk of Mortality; PT, Prothrombin time; SD, standard deviation.
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NK: natural killer; PE: plasma exchange; PELOD: Pediatric Logistic Organ
Dysfunction; PRISM: Pediatric Risk of Mortality; PT: prothrombin time; SIRS:
systemic inflammatory response syndrome; TPV: total plasma volume.
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